InvestSMART

Prescient Therapeutics Limited (ASX: PTX) - Share Price

Current share price for PTX : $0.068 0.001 (1.49%)+

Prescient Therapeutics (PTX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

PTX General Information +

ASX Code PTX
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 71
PTX Share Price $0.068
Day High $0.069
Day Low $0.067
Last Close $0.067
PTX Share Price Movement $0.00 ( 1.49% )
Prices as at 16:40, 4 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Prescient Therapeutics Limited (PTX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Prescient Therapeutics Limited (PTX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Prescient Therapeutics Limited (PTX) price-sensitive announcements

PTX - Prescient Therapeutics Opens SPP to Raise $7m Today
Prescient Therapeutics Limited (PTX), an Australian clinical-stage oncology company, has i
Prescient Therapeutics Limited (PTX)
26 Aug 2026 | 8:57 AM
PTX - Prescient Therapeutics Launches Share Purchase Plan for $7m
Prescient Therapeutics Limited (ASX: PTX), an Australian clinical-stage oncology company,
Prescient Therapeutics Limited (PTX)
25 Aug 2026 | 9:06 AM
PTX - Appendix 4E and 2026 Annual Report
Prescient Therapeutics Limited's 2026 Annual Report and Appendix 4E outline the financial
Prescient Therapeutics Limited (PTX)
21 Aug 2026 | 9:32 AM
PTX - June 2026 Quarterly Update and Appendix 4C
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, reported sig
Prescient Therapeutics Limited (PTX)
27 Jul 2026 | 12:36 PM

Prescient Therapeutics Limited (PTX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $72 PTX-100 CTCL Phase 2a study reaches review milestone 2 Sep 2026 2:10PM $0.067 $0.068 risen by 1.49%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $72 Prescient Share Purchase Plan Investor Presentation 26 Aug 2026 9:53AM $0.067 $0.068 risen by 1.49%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $72 Prescient Therapeutics Opens SPP to Raise $7m Today 26 Aug 2026 8:57AM $0.067 $0.068 risen by 1.49%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $72 Share Purchase Plan Cleansing Notice 26 Aug 2026 8:45AM $0.067 $0.068 risen by 1.49%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $72 Proposed issue of securities - PTX 25 Aug 2026 2:47PM $0.066 $0.068 risen by 3.03%
Prescient Therapeutics Limited (PTX)
ORDINARY FULLY PAID
Health Care $72 Prescient Therapeutics Launches Share Purchase Plan for $7m 25 Aug 2026 9:06AM $0.072 $0.068 fallen by 5.56%

PTX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$7.00 -$0.70 -25.30% 0.00 0.00 0.00% 0.0%
2025A -$7.32 -$0.90 12.40% 0.00 0.00 0.00% 0.0%
2024A -$6.52 -$0.80 -15.60% 0.00 0.00 0.00% 0.0%

PTX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $84,049M 0.7309 -0.4417 0.0505 10.8726 19.4730 18.5369 2.42% 2.38% 2.46%
Clinuvel Pharmaceuticals Limited (CUV) $417M -0.0696 -0.0719 0.0242 12.3653 13.3226 13.0079 0.61% 0.61% 0.61%
Mesoblast Limited (MSB) $3,091M -0.4380 0.0000 0.0000 0.0000 0.0000 377.7778 0.00% 0.00% 0.00%
Prescient Therapeutics Limited (PTX) $70M -0.2527 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,525M -1.3893 0.0000 -0.9095 0.0000 154.8571 1,711.5789 0.00% 0.00% 0.00%

PTX Directors

Name Position Start Date
Ms Melanie Farris Non-Executive Director 10 Apr 2025
Dr Allen James Ebens Non-Executive Director 1 Jun 2020
Dr Ellen Gwen Feigal Non-Executive Director 15 May 2023
Dr Gavin James Shepherd Non-Executive Director 4 Jul 2024
Dr James Campbell Non-Executive Director, Non-Executive Chairman 28 Nov 2014

Prescient Therapeutics Limited (PTX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
4 Aug 2025 FARRIS, Melanie Buy Indirect Shares 375,000 $0.040 $15,000.000
4 Aug 2025 SHEPHERD, Gavin Buy Indirect Shares 500,000 $0.040 $20,000.000
4 Aug 2025 CAMPBELL, James Buy Indirect Shares 750,000 $0.040 $30,000.000

See all changes in directors' interest & trades for Prescient Therapeutics Limited (PTX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PTX Management

Name Position
James McDonnell Chief Executive Officer
Melanie Jaye Leydin Chief Financial Officer,Company Secretary

PTX Calendar of Events

Date Event
20 August 2027 Report (Annual)
20 August 2027 Report (Prelim)
23 February 2027 Report (Interim)
14 October 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.